Preoperative ELISpot responses | Group A | Group B |
Tumour free (n=34) | Tumour recurred (n=10) | |
Total PPD-specific responses | 91% | 100% |
31/34 | 10/10 | |
Suppressed PPD responses | 65% | 60% |
20/31 | 6/10 | |
Total HA-specific responses | 74% | 80% |
25/34 | 8/10 | |
Suppressed HA responses | 64% | 50% |
16/26 | 4/8 | |
Total 5T4-specific responses | 44% | 40% |
15/34 | 4/10 | |
Suppressed 5T4 responses | 73% | 100% |
11/15 | 4/4 | |
Total CEA-specific responses | 41% | 70% |
14/34 | 7/10 | |
Suppressed CEA responses | 50% | 100% |
7/14 | 7/7 |
Ex-vivo IFN-γ responses to control antigens (PPD and HA) and the tumour antigens (5T4 and CEA) by whole and Treg depleted peripheral blood mononuclear cells was determined by ELISpot. The number and proportion of patients that made a response and whether the response was suppressed by Tregs is shown. Data are shown for 44 patients for whom 12 month clinical outcome data were available.
CEA, carcinoembryonic antigen; HA, haemagglutinin; PPD, purified protein derivative.